Closes with security. Leaves without a trace.*

The sealant is resorbed by the body within 30 days.
**Close with Confidence. Leave Nothing Behind**.

MYNX CONTROL™ Vascular Closure Device features a redesigned, ergonomic handle to facilitate ease-of-use and predictable deployment.

### The Science of Active Extravascular Sealing

**MYNX™ GRIP TIP**

**MYNX™ Sealant**

MYNX CONTROL™ VCD is comprised of two configurations of polyethylene glycol (PEG), for durable hemostasis.

### Proven PEG Material

- **SAFE**  No foreign-body reaction or scar tissue formation
- **SYNTHETIC**  Non-thrombogenic
- **HYDROLYTIC DEGRADATION**  Fully resorbs through hydrolysis—no enzymatic breakdown

### Dual-mode Active Sealing

1. **MYNX™ GRIP TIP**

2. **MYNX™ SEALANT COLUMN**

**FULLY EXTRAVASCULAR CLOSURE**

- Activated by body temperature and pH
- Interlocks with contours of the vessel by actively attaching to the artery, for secure mechanical closure
- Expands to 3-4 times its original size on contact with blood and subcutaneous fluids, creating a matrix structure for clot formation
- Provides further support for the MYNX™ GRIP TIP

### Secure Extravascular Closure

in a wide range of clinical scenarios

Clinically versatile, MYNX CONTROL™ VCD offers dependable closure with nothing left behind—treats a wide range of patients and clinical scenarios.

- Safe closure below the femoral bifurcation
- Useful on antegrade punctures
- No footplates, sutures, or metal implants to impede reaccess
- Balloon visualization verifies position

---

*The sealant is resorbed by the body within 30 days.

†Confirm vessel size is ≥ 5mm
MYNX™ VCD has been clinically proven to reduce surgical complications, expedite recovery, shorten hospital stays, and increase patient comfort.2,7

Safety and Efficacy in Interventions
A single-center, multi-year comparative analysis involving 4,074 percutaneous coronary intervention (PCI) patients found MYNX™ VCD to be equally safe and effective as Angio-Seal™, with no intra-arterial components left behind.4

Safety in Clinical Trials and Real-world Use
In a prospective multi-center, non-randomized clinical trial (n=190) MYNX™ VCD demonstrated2,8:

99.5% Procedure success rate

1.3 MIN Time to hemostasis

In a real-world cohort of 432 patients undergoing coronary angiography, MYNX™ VCD demonstrated5:

99.5% Same-day discharge

Reduced Risk and Severity of Complications
In a retrospective, single-center review of 11,006 cardiac and peripheral vascular procedures, MYNX™ VCD was proven to reduce the risk and severity of surgical complications following catheterization, compared to Angio-Seal™ and manual compression.6

Increased Patient Comfort
In a blinded, randomized clinical study, pain at closure and pain increase from baseline to close were significantly lower for MYNX™ VCD than Angio-Seal™.7

10x fewer secondary surgeries than Angio-Seal™6
3x fewer secondary surgeries than manual compression5
MYNX™ VCD complications did not involve embolism or artery damage, worsening of peripheral vascular disease, or necessitate device removal6

99.5% Rate of surgical repair

Less pain than Angio-Seal™

‡Time to discharge eligibility as compared to manual compression. MATRIX Clinical Trial (IDE # G030182). Data on file.
The next-generation MYNX CONTROL™ Vascular Closure Device (VCD) deployment system is purpose-designed to enhance safety and deliver reliable performance.

Made for Predictable Deployment. Designed for Ease of Use.

Procedure Steps

1. DEPLOY THE BALLOON
   - Achieve temporary hemostasis and position at the arteriotomy.

2. PLACE THE SEALANT
   - The MYNX™ GRIP TIP securely adheres to the artery and MYNX™ Sealant fills the tissue tract.

3. REMOVE THE DEVICE
   - Platelets and blood cells collect inside the sealant’s porous matrix.

4. FINAL RESULT
   - The sealant dissolves within 30 days, leaving nothing behind but a healed artery.

$MYNX CONTROL™ VCD is incompatible with Medtronic Input® Introducer (11cm) sheaths, Cook Check-Flo® Performer® Introducer sheaths, and procedural sheaths longer than 12cm in effective length.
Closes with Security. Leaves Without a Trace.*

MYNX CONTROL™ Vascular Closure Device (VCD) integrates dual-mode active sealing and resorbability with a next-generation delivery system to maximize predictability, safety, and ease of use.

*The sealant is resorbed by the body within 30 days.

Ordering Information
The MYNX CONTROL™ VCD includes:

(1) MYNX CONTROL™ VCD including balloon catheter and integrated polyethylene glycol sealant
(1) 10ml locking syringe

<table>
<thead>
<tr>
<th>SIZE</th>
<th>EMEA ORDER NUMBER</th>
</tr>
</thead>
<tbody>
<tr>
<td>5F</td>
<td>MX5060E</td>
</tr>
<tr>
<td>6F/7F</td>
<td>MX6760E</td>
</tr>
</tbody>
</table>

To order the MYNX CONTROL™ VCD contact your local Cordis sales representative or customer service. Visit cardinalhealth.co.uk to learn more.


INDICATIONS FOR USE: MYNX CONTROL™ VCD is indicated for use to seal femoral arterial access sites while reducing times to hemostasis and ambulation in patients who have undergone diagnostic or interventional endovascular procedures utilizing a 5F, 6F, or 7F procedural sheath.

PRECAUTIONS: MYNX CONTROL™ VCD should only be used by a trained licensed physician or healthcare professional. MYNX CONTROL™ VCD should not be used in patients with a known allergy to PEG. MYNX CONTROL™ VCD should not be used with sheaths longer than 12cm effective length or incompatible sheaths listed in Table 1 of the Instructions for Use.

WARNINGS: Do not use if components or packaging appear to be damaged or defective or if any portion of the packaging has been previously opened. DO NOT REUSE OR RESTERILIZE. MYNX CONTROL™ VCD is for single use only. The catheter is loaded with a single hydrogel sealant. Reuse of the device would result in no delivery of hydrogel sealant. Do not use MYNX CONTROL™ VCD if the puncture site is located above the most inferior border of the inferior epigastric artery (IEA) and/or above the inguinal ligament based upon bony landmarks, since such a puncture site may result in a retroperitoneal hematoma/bleed. Perform a femoral angiogram to verify the location of the puncture site. Do not use MYNX CONTROL™ VCD if the puncture is through the posterior wall or if there are multiple punctures, as such punctures may result in a retroperitoneal hematoma/bleed.

For Healthcare Professionals Only. Important information: Prior to use, refer to the Instructions for Use supplied with this device for indications, contraindications, side effects, suggested procedure, warnings and precautions. As part of its continuous product development policy, Cordis reserves the right to change product specifications without prior notification. CORDIS, the Cordis LOGO and MYNX CONTROL are trademarks of Cardinal Health and may be registered in the US and/or in other countries. © 2019 Cardinal Health. All Rights Reserved. 100538826 06/2019